Nephros, Inc. (NASDAQ:NEPH – Get Free Report) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 4,900 shares, a decline of 36.4% from the November 30th total of 7,700 shares. Based on an average daily volume of 11,400 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the stock are sold short.
Nephros Stock Up 0.7 %
Shares of NEPH stock traded up $0.01 on Friday, reaching $1.49. The company had a trading volume of 5,065 shares, compared to its average volume of 14,313. The business’s 50-day moving average is $1.52 and its 200 day moving average is $1.79. Nephros has a one year low of $1.36 and a one year high of $4.04. The stock has a market capitalization of $15.71 million, a PE ratio of -16.56 and a beta of 1.21.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Nephros stock. Dimensional Fund Advisors LP bought a new position in Nephros, Inc. (NASDAQ:NEPH – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned approximately 0.17% of Nephros as of its most recent SEC filing. Institutional investors and hedge funds own 41.10% of the company’s stock.
Analyst Ratings Changes
Nephros Company Profile
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Stories
- Five stocks we like better than Nephros
- Industrial Products Stocks Investing
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- About the Markup Calculator
- Top 3 ETFs to Hedge Against Inflation in 2025
- 3 Monster Growth Stocks to Buy Now
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.